‹ Back to NATCOPHARM.NS

NATCOPHARM.NS Cash Flow

NATCO Pharma Ltd.

Profit & Loss Balance Sheet Cash Flow

Cash Flow · 6 years on file (FY2020-21 to FY2025-26) · fetched 2026-08-23 23:38
Line item FY2020-21 FY2021-22 FY2022-23 FY2023-24 FY2024-25 FY2025-26 Source (XBRL element)
Net Cash from Operating Activities N/A ₹46.50 Cr. ₹849.10 Cr. ₹1,211.60 Cr. ₹1,696.80 Cr. ₹1,768.30 Cr. CashFlowsFromUsedInOperatingActivities
Net Cash from Investing Activities N/A ₹-5.30 Cr. ₹-477.10 Cr. ₹-1,032.70 Cr. ₹-1,414.50 Cr. ₹-2,142.90 Cr. CashFlowsFromUsedInInvestingActivities
Net Cash from Financing Activities N/A ₹34.80 Cr. ₹-363.00 Cr. ₹-246.90 Cr. ₹-210.70 Cr. ₹297.50 Cr. CashFlowsFromUsedInFinancingActivities
Effect of Exchange Rate Changes N/A ₹9.30 Cr. ₹11.80 Cr. ₹6.50 Cr. ₹-22.00 Cr. ₹156.00 Cr. EffectOfExchangeRateChangesOnCashAndCashEquivalents
Net Increase/(Decrease) in Cash N/A ₹85.30 Cr. ₹20.80 Cr. ₹-61.50 Cr. ₹49.60 Cr. ₹78.90 Cr. IncreaseDecreaseInCashAndCashEquivalents
Cash and Cash Equivalents (Closing) N/A ₹25.80 Cr. ₹111.10 Cr. ₹131.90 Cr. N/A N/A CashAndCashEquivalentsCashFlowStatement

Every figure above is the exact value of the named XBRL element from NATCOPHARM.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).